Compare Enveric Biosciences Inc (ENVB) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Okta, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Okta, Inc. trades at $150.46 (market cap $26.22B). The key difference: Okta, Inc. is far larger — about 4928.6× Enveric Biosciences Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | OKTA | |
|---|---|---|
Market Cap | $5.32M | $26.22B |
Sector | Health | Technology |
52-Week High | $17.40 | $154.62 |
52-Week Low | $1.28 | $62.93 |
Enterprise Value | $408.82K | $24.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
OKTA trades at $150.97, down 2.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported revenue of $2.61B in 2025, achieving positive net income of $28M after years of losses, and has beaten earnings estimates for three consecutive quarters. Analyst consensus is strongly bullish with 72.55% buy ratings, though the stock trades above the consensus price target of $125.78.
The outlook for OKTA is positive due to robust revenue growth, improving profitability, and strong demand for AI-driven cybersecurity solutions. Key risks include high valuation multiples, intense competition, and sensitivity to enterprise IT spending cycles. The stock presents a growth opportunity but requires monitoring of execution and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
